reports
Acerus Update
Acerus Update TORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company”) announces that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) and its previously announced sale and investment solicitation process (the “SISP”), the Company completed the previously announced transactions (the “Transaction”) with First Generation Capital Inc. (“First Generation”) as successful bidder under the SISP. The Transaction was approved by the Ontario Superior Court of Justice (Commercial List) (the “Court...
Acerus Update
Acerus Update TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- As announced on January 26, 2023, Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) and its subsidiaries were granted creditor protection pursuant to an order (the “Initial Order”) granted by the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). Pursuant to the Initial Order, Ernst & Young Inc. was appointed as monitor of the Company (in such capacity, the “Monitor”). As announced on March 14, 2023, the Court granted an order (the “SISP Ord...
Acerus Announces Commencement of Court-Approved Sale and Investment So...
Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and certain of its subsidiaries (collectively, “Acerus”) were granted protection pursuant to an order (the “Initial Order”) issued under the Companies’ Creditors Arrangement Act (the “CCAA Proceedings”) by the Ontario Superior Court of Justice (the “Canadian Court”). Ernst & Young Inc. was appointed Monitor of Acerus (in such capacity, the “Monitor”). On February 3, 2023, the Initial Order was amended a...
Acerus Files For CCAA Protection
Acerus Files For CCAA Protection TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA, LLC (collectively, the “Acerus Group”), have received an order for creditor protection (the “Initial Order”) from the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). As previously disclosed on September 21, 2022, Acerus unde...
Acerus Announces Resignation of Director
Acerus Announces Resignation of Director TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately. About Acerus Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. Acerus’ shares trade on TSX under the symbol AS...
Acerus Announces New Loan Agreement With First Generation Capital
Acerus Announces New Loan Agreement With First Generation Capital TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that it and its wholly-owned subsidiary, Acerus Pharmaceuticals USA, LLC (collectively with the Company, the “Borrowers”), have entered into a US$2 million secured loan agreement (the “Loan Agreement”) with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus.1 Funds under the Loan Agreement will be made av...
Acerus Reports Third Quarter 2022 Financial Results
Acerus Reports Third Quarter 2022 Financial Results TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and nine-month period ended September 30, 2022. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Recent Highlights Total Natesto® prescriptions in the US rose 69% year-over-year in the third quarter of 2022 and were up approximately 10% sequentially over...
Acerus Announces Amendment to Promissory Note Due to Former Serenity S...
Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has amended the promissory note (the “Note”) in the amount of US$4.91 million related to the up-front fee owed to former Serenity Pharmaceuticals LLC (“Serenity”) securityholders. The securityholder representative and Acerus agreed that the amount of the note would be increased to US$7.75 million. Repayment of the Note would be done via a payment schedule co...
Acerus Announces Initiation of Strategic Review
Acerus Announces Initiation of Strategic Review Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisors TORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Board of Directors has determined to undertake a strategic review of capital and business alternatives, including a possible debt or equity financing, asset sale, M&A, or licensing transaction. The Board has struck a committee of independent directors to supervise this strategic review process....
Acerus Announces Resignation of CFO Effective November 20, 2022
Acerus Announces Resignation of CFO Effective November 20, 2022 TORONTO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that Robert Motz has informed the Company of his decision to resign as Chief Financial Officer effective November 20, 2022. Acerus has begun a process to search for a new CFO and will provide an update at a future date. “I would like to thank Bob for his contributions over the past four years,” said Edward Gudaitis, President and Chief Executive Officer of Acerus Pharmaceuticals. “...
Acerus Reports Second Quarter 2022 Financial Results
Acerus Reports Second Quarter 2022 Financial Results TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and six-month period ended June 30, 2022. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Recent Highlights Total Natesto® prescriptions in the US rose 47% year-over-year in the second quarter of 2022 and were up approximately 23% sequentially over the fiscal 2...
Acerus Announces Amendments to Loan Facility and Promissory Note Due t...
Acerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity Shareholders TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus1, to increase its existing secured loan facility (the “Loan Facility”) from US$37.945 million to US$47.945 million. This increase will be made available to the Company by...
Acerus to Report Q2-2022 Financial Results and Host Investor Call
Acerus to Report Q2-2022 Financial Results and Host Investor Call TORONTO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2022 financial and operating results on Tuesday, August 9, 2022 before the market opens. The company will also host a conference call on Tuesday, August 9, 2022 at 10:00 a.m. Eastern Time. To access the call live, please dial 416-340-2217 or 1-800-806-5484 and use access code 2534277#. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conf...
Acerus Announces Voting Results for the 2022 Annual Meeting
Acerus Announces Voting Results for the 2022 Annual Meeting TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced the voting results from its annual meeting of shareholders held on June 27, 2022. The total number of shares represented in person or by proxy at the meeting was 6,923,589, representing 89.83% of the total issued and outstanding Acerus shares. Election of Directors The seven (7) candidates nominated for election to the Acerus board of directors and listed in Acerus’ management information circular da...
Acerus Announces Amendments to Loan Facility
Acerus Announces Amendments to Loan Facility TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus1, to increase its existing secured loan facility (the “Loan Facility”) from US$35.845 million to US$37.945 million. This increase was made available to the Company by way of a single advance of US$2.1 million on June 23, 2022 ...
Acerus Announces Amendment and Restatement of the Promissory Note Rela...
Acerus Announces Amendment and Restatement of the Promissory Note Related to the Up-Front Fee Payable to Former Serenity Securityholders TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCD) today announced that it has entered into an amended and restated promissory note (the “A&R Note”) covering the up-front fee owed to former Serenity Pharmaceuticals LLC (“Serenity”) securityholders. Under the original promissory note, the up-front fee, less deductions, in the amount of US$4.91 million was due to be paid on June ...
Acerus Reports First Quarter 2022 Financial Results
Acerus Reports First Quarter 2022 Financial Results TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2022. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Recent Highlights Total Natesto® prescriptions in the US rose 43% year-over-year in the first quarter of 2022 and were up approximately 26% sequentially over the fiscal 2021 fourth...
Acerus To Report Q1-2022 Financial Results And Host Investor Call
Acerus To Report Q1-2022 Financial Results And Host Investor Call TORONTO, May 05, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCD) will announce its first quarter 2022 financial and operating results on Tuesday, May 10, 2022 before the market opens. The company will also host a conference call on Tuesday, May 10, 2022 at 10:00 a.m. Eastern Time. To access the call live, please dial 416-406-0743 or 1-800-898-3989 and use access code 3384602#. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference...
Acerus Announces Completion of Share Consolidation
Acerus Announces Completion of Share Consolidation TORONTO, April 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) announced that further to its news release from April 19, 2022, the Company’s application to consolidate its common shares (“Shares”) on the basis of one (1) post-consolidation Share for every two hundred (200) pre-consolidation Shares (the “Consolidation”) has been accepted by the Toronto Stock Exchange. Prior to implementing the Consolidation, the Company had approximately 1,541,549,299 Shares issued and out...
Acerus Announces Share Consolidation
Acerus Announces Share Consolidation TORONTO, April 19, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that the Company intends to undertake a consolidation of its outstanding common shares on the basis of one (1) post-consolidation share for every two hundred (200) pre-consolidation shares (the “Consolidation”). The Consolidation was previously approved by shareholders of the Company at the annual and special meeting of shareholders of the Company held on June 14, 2021. Subject to the approval of the Toronto...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.